Gyorgy Baffy (@gbaffy) header
Gyorgy Baffy (@gbaffy) profile picture

Gastroenterologist, researcher, teacher. Harvard Medical School and VA Boston. With one eye on fatty liver and the other aimed at the many wonders of life.

Boston, MA
Joined December 2009
Photo by Gyorgy Baffy (@gbaffy)Photo by Gyorgy Baffy (@gbaffy)Photo by Gyorgy Baffy (@gbaffy)Photo by Gyorgy Baffy (@gbaffy)Photo by Gyorgy Baffy (@gbaffy)Photo by Gyorgy Baffy (@gbaffy)Photo by Gyorgy Baffy (@gbaffy)Photo by Gyorgy Baffy (@gbaffy)Photo by Gyorgy Baffy (@gbaffy)Photo by Gyorgy Baffy (@gbaffy)
Glad to share our recent paper in @eClinicalMed on the use of machine learning in predicting trajectories and outcomes in early-stage #masld secure-web.cisco.com/1MUeQWb…
1
64
Glad to share our latest work published in @JHepatology on #mechanotransduction and #NAFLD. The following link will allow anyone to have free access for the next few weeks: authors.elsevier.com/a/1fqhX…
3
Glad to see our provocative piece written with the great @jaumebosch9 on subclinical #portal hypertension in @JHepatology, promoting the paradigm that mechanosignaling pathways in #NAFLD link early increase in #sinusoidal pressure to #fibrosis authors.elsevier.com/a/1e6SO…
1
6
24
Just published a brief letter in @JHepatology arguing to keep #NAFLD as an acronym over #MAFLD as a newly proposed term. The new conceptual framework is great, but the familiar abbreviation could remain if 'nonalcoholic' becomes 'nutrition-associated'! authors.elsevier.com/a/1cTtv…
1
2
Thank you @AASLDtweets for a terrific #TLMdX that allowed so many friends, colleagues, and even #NobelPrize2020 laureates to bring the best and latest in our field straight to my living room during the past 4 days! @AASLDPresident @bezerratweet @MichiganLiver @raychungmd
1
1
14
Glad to share our recent OA review on #NAFLD and portal hypertension explorationpub.com/Journals/… describing EUS-guided measurement of the portal pressure gradient and set to change the perception that PPG is not a major player until it is high enough to call "clinically significant"
1
2
12
Gyorgy Baffy retweeted
Replying to @HollyJGreen
I guess a truly international palindrome will never happen again as long as there are some *crazy* languages such as Hungarian in which the date begins with the year (2020.02.02). Fortuitously, however, the Hungarian version happens to be just another palindrome! @HollyJGreen
1
2
Retirement dinner honoring Raj Goyal to mark an era of renowned clinical research and outstanding patient care at @VABostonHC as we all continue to look for guidance and wisdom from this humble giant and pioneer of gastrointestinal physiology. @AmerGastroAssn @AGA_Gastro
5
Interim regenerate phase 3 (OCA) results are published. No efficacy on NASH endpoint. A signal on fibrosis with only 25mg, but can’t ignore 50% who get pruritus and 9% drop out. Really need to know predictors of response #Nash @IanARowe @phil_newsome7 @drrichardparker
1
18
29
Leon Schiff state-of-the-art lecture by Dr Josip Llovet @MountSinaiNYC and @BCLC_group on molecular pathogenesis and management of #HCC @AASLDtweets #LiverMtg19
2
2
#FMT affects brain inflammation and glia activation: @JasmohanBajaj transplanted stools of HE patients into germ-free mice and found higher frontal cortex markers IBA-1, IL1beta and MCP-1 if FMT done before abx Rx. Stool supernatant had no effect. @AASLDtweets #LiverMtg19
3
6
Is there a universal biomarker panel to predict #cirrhosis in #NAFLD? Dr TG Oh @salkinstitute @UCSDHealth reports on combined signatures of 19 gut microbiota species and 17 novel microbial metabolites such as kynurenic acid, enterolactone and vit D3 @AASLDtweets #LiverMtg2019
1
Caveat added by @JasmohanBajaj to biomarker study @salkinstitute @UCSDHealth: Do not compare apple to oranges and lump comp/decomp cirrhosis cohorts, but also look at patients to judge their advanced status rather than at their #microbiome @AASLDtweets #LiverMtg19
Saroglitazar effects in 106 noncirrhotic #NAFLD cases, reported by Dr Gawrieh @IUHepatology. Primary endpoint ALT drop at 16wks met at all doses with 44% peak reduction. HOMA-IR (but not A1c), TG, HDL, PDFF and ELF impact only significant at 4mg. @AASLDtweets #LiverMtg19
Innovative therapy for #alcoholic hepatitis? Dr Hassanein from Southern California GI and Liver Centers on early results with the sulfated oxysterol DUR-928, a cytotoxic molecule with gene regulatory properties and antifibrotic effects @AASLDtweets #LiverMtg19
2
8
1
14
DUR-928 was tolerated at 30, 90, and 150mg parenteral doses in #alcoholic hepatitis patients with overall DF ~53 and responding with average <0.19 Lille scores and ~5 MELD drop @AASLDtweets #LiverMtg19
1
4
LIFT-HDV phase 2a study report on using lonafarnib, ritonavir and PEF-IFN lambda for 24 weeks in delta hepatitis by Dr Christopher Koh. Primary endpoint >2log #HDV RNA decline from 4.74 baseline average was met with 3.18 log drop at 24wks @NIH @NIDDKgov @AASLDtweets #LiverMtg19
5
1
10
Licogliflozin improved A1c and liver PDFF in #NAFLD with both 30 and 150mg dosing at 12 weeks with mixed and mild effect of fibrosis markers as reported by Dr Stephen Harrison @AASLDtweets #LiverMtg19
4
4
Same place, (almost) same time: Liver Meeting 2020 back to Boston #LiverMtg19 @AASLDtweets
Wrapping up #LiverMg19 with new promises: Late-breaking abstract session begins with interim analysis of phase 2a LIK066X2204, licogliflozin 30 vs 150mg in bx-proven or diabetic #NAFLD. ALT decrease is only primary endpoint, met with higher dose after 12 @AASLDtweets
2
3